Helixgate https://validator.w3.org/feed/docs/rss2.html Circular mRNA helps cell factories make up to six times as much protein Diabetes Drug Face-Off: New Japanese Trial Tests Whether a Popular SGLT2 Inhibitor Eats Away at Muscle Open-Source Machine Learning Workflow Accelerates Discovery of Small-Molecule PD-L1 Cancer Inhibitors StockWatch: Novo’s 2030 Strategy Underwhelms Investors at Capital Markets Day Emerging Trends in Fluid Transfers and Freeze-Thaw Workflows Advancing Cell Therapy for Cardiovascular Disease Best Practices for Establishing Data Integrity in Western Blotting Advancing AAV Development: From Production to Performance STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators STAT+: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO Boehringer, Envisagenics sign $1B multi-target oncology collaboration J&J firms up Caplyta’s 1st phase 3 win in bipolar-associated manic episodes New MFN deal details reignite concerns that Trump’s pricing policy favors pharma Novo struggles to appease restive investors with consumer plans, blockbuster ambitions Bayer offloads cancer drug Stivarga to Grünenthal for up to $431M as new competition looms Changing expectations: How GRAM is strengthening CDMO partnerships How Learning Systems Move Pharma Marketing Beyond the Box Score How J&J paved the way for Compass’ coming psychedelic drug launch Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’ Beacon eye gene therapy hits mark in late-stage study Novo talks up drug launches in effort to win back investors Telix to buy radiopharma rival ITM for $1.65bn upfront Beacon’s XLRP gene therapy set for filing after phase 3 win Advocacy group pokes holes in Trump’s MFN pricing claims PDUFA VIII aims to remove CMC bottlenecks, shore up FDA staffing Chugai’s Lasker winners aim to beat their own blockbuster Biotech IPOs, CAR T safety, and pharma tariffs — a BioCentury podcast Telix-ITM merger aims to create radiopharma juggernaut: Deals Report Beacon edges ahead in XLRP gene therapy race with Phase III hit Novo buys three early-stage obesity assets from Kallyope as investor pressure mounts Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts Deep Dive: How AI is now essential in biopharma Sandoz and mAbxience agree on emicizumab biosimilar partnership Telix to acquire ITM in deal worth up to $2.35bn STAT+: With new strategy, Novo outlines plans for obesity, direct-to-consumer work STAT+: Lilly’s breast cancer combo wins approval Convenience Kit Correction: AVID Medical Issues Correction for Kits Containing Huons Sodium Chloride Ampules A hidden tradeoff in Trump’s MFN drug deals FDA Roundup: July 26, 2024 FDA Roundup: June 18, 2024 FDA Updates Regulations to Advance Innovative Alternatives to Animal Testing Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP Due To a Product Mix-up with 10 mEq Potassium Chloride Injection Par Health Issues Voluntary Nationwide Recall of Two Lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection Due to the Presence of Particulate Matter Two trials or not two trials? That should not be the question The evolving landscape of drug targets Home